Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
63High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07349043CT.gov A Prospective, Safety, and Efficacy Clinical Trial of Pressurized Intraperitoneal Aerosol Therapy for Peritoneal Metastasis of Colorectal Cancer | — | Recruiting | — | — | — |
NCT06423937CT.gov Fruquintinib Plus Camrelizumab and HAIC in the Treatment of Non-MSI-H Advanced Colorectal Cancer | — | Not Yet Recruiting | — | — | — |
NCT06525428CT.gov Standard Systemic Therapy Combined With High/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer | — | Recruiting | — | — | — |
NCT05435313CT.gov Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard Therapy | — | Unknown | — | — | — |
NCT04761185CT.gov Raltitrexed in HIPEC | — | Completed | — | — | — |
NCT04241731CT.gov A Study of Cetuximab Plus Raltitrexed for Maintenance Treatment in Advanced Colorectal Cancer | — | Unknown | — | — | — |
NCT03813641CT.gov RALOX or CAPOX + Bevacizumab in the First-line Treatment of Advanced CRC(ROCB Study) | — | Unknown | — | — | — |
NCT04499586CT.gov A Study of Radiotherapy Combined With Raltitrexed and Irinotecan in Metastatic or Locally Recurrent Colorectal Cancer | — | Unknown | — | — | — |
NCT03344614CT.gov A Study of Apatinib in Combination With Raltitrexed Treatment in Patients With Advanced Colorectal Cancer | — | Unknown | — | — | — |
NCT03126071CT.gov Raltitrexed-based Chemotherapy Plus Bevacizumab in Retreated Patients With Advanced Colorectal Cancer | — | Unknown | — | — | — |
Show 7 more trialsShow fewer
NCT03053167CT.gov Irinotecan Plus Raltitrexed as Second-line Treatment in Advanced Colorectal Cancer Patients | — | Unknown | — | — | — |
NCT02821559CT.gov Biweekly Versus Triweekly Raltitrexed With Oxaliplatin (With or Without Bevacizumab) in First-line Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT01532804CT.gov 2nd-line Treatment of Metastatic Colorectal Cancer | — | Terminated | — | — | — |
NCT01348412CT.gov Hepatic Arterial Chemotherapy With Raltitrexed and Oxaliplatin Versus Standard Chemotherapy in Unresectable Liver Metastases From Colorectal Cancer After Conventional Chemotherapy Failure | — | Completed | — | — | — |
NCT00234429CT.gov A Phase 2 Study of Tomudex & Iressa as Second Line Chemotherapy in Subjects With Colorectal Carcinoma | — | Completed | — | — | — |
NCT00002893CT.gov Palliative Chemotherapy in Treating Patients With Advanced Colorectal Cancer | — | Unknown | — | — | — |
NCT00002828CT.gov Chemotherapy With Raltitrexed and Fluorouracil in Treating Patients With Advanced Colorectal Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Colorectal Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Raltitrexed (this asset) | Second Affiliated Hospital, School of Medicine, Zhejiang University | P3 | B · 62 |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BBB |
| Marble Dust | James Varani | P2/3 | BB |
| Oxaliplatin | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | P4 | BB |
| Orectalip | Sinphar Pharmaceutical Co., Ltd | P4 | BB |
| Fluorouracilum | UNICANCER | P4 | BB |
| Levofolinic Acid | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | P3 | BB |
| Fentanyl | Mansoura University | P4 | BB |
| Panitumumab | MSPU des 3 Provinces | P3 | BB |
+42 more in the Colorectal Cancer cohort
Other indications for Raltitrexed
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Rectal Cancer | — | P2 | B · 62 |
| Hepatocellular Carcinoma | — | P3 | B · 60 |
| Rectal Carcinoma | — | P2 | CCC · 54 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Raltitrexed in Colorectal Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/raltitrexed-colorectal-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →